These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 23860535)
1. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Ceresoli GL; Zucali PA; Mencoboni M; Botta M; Grossi F; Cortinovis D; Zilembo N; Ripa C; Tiseo M; Favaretto AG; Soto-Parra H; De Vincenzo F; Bruzzone A; Lorenzi E; Gianoncelli L; Ercoli B; Giordano L; Santoro A Br J Cancer; 2013 Aug; 109(3):552-8. PubMed ID: 23860535 [TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Dowell JE; Dunphy FR; Taub RN; Gerber DE; Ngov L; Yan J; Xie Y; Kindler HL Lung Cancer; 2012 Sep; 77(3):567-71. PubMed ID: 22770372 [TBL] [Abstract][Full Text] [Related]
3. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion. Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740 [TBL] [Abstract][Full Text] [Related]
4. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684 [TBL] [Abstract][Full Text] [Related]
6. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604 [TBL] [Abstract][Full Text] [Related]
7. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option? Li L; Razak AR; Hughes A Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Castagneto B; Botta M; Aitini E; Spigno F; Degiovanni D; Alabiso O; Serra M; Muzio A; Carbone R; Buosi R; Galbusera V; Piccolini E; Giaretto L; Rebella L; Mencoboni M Ann Oncol; 2008 Feb; 19(2):370-3. PubMed ID: 18156144 [TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. Hughes A; Calvert P; Azzabi A; Plummer R; Johnson R; Rusthoven J; Griffin M; Fishwick K; Boddy AV; Verrill M; Calvert H J Clin Oncol; 2002 Aug; 20(16):3533-44. PubMed ID: 12177114 [TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer. Stevenson JP; Langer CJ; Somer RA; Evans TL; Rajagopalan K; Krieger K; Jacobs-Small M; Dyanick N; Milcarek B; Coakley S; Walker S; Eaby-Sandy B; Hageboutros A Cancer; 2012 Nov; 118(22):5580-7. PubMed ID: 22544579 [TBL] [Abstract][Full Text] [Related]
14. NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. Dy GK; Molina JR; Qi Y; Ansari R; Thomas S; Ross HJ; Soori G; Anderson D; Aubry MC; Meyers J; Adjei AA; Mandrekar S; Adjei AA J Thorac Oncol; 2014 Aug; 9(8):1146-53. PubMed ID: 25157767 [TBL] [Abstract][Full Text] [Related]
15. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience. Malhotra B; Evans T; Weiss J; Eaby B; Stonehouse-Lee S; Sherry V; Langer CJ Clin Lung Cancer; 2010 May; 11(3):192-7. PubMed ID: 20439196 [TBL] [Abstract][Full Text] [Related]
16. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Katirtzoglou N; Gkiozos I; Makrilia N; Tsaroucha E; Rapti A; Stratakos G; Fountzilas G; Syrigos KN Clin Lung Cancer; 2010 Jan; 11(1):30-5. PubMed ID: 20085865 [TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. Casey EM; Harb W; Bradford D; Bufill J; Nattam S; Patel J; Fisher W; Latz JE; Li X; Wu J; Hanna N J Thorac Oncol; 2010 Nov; 5(11):1815-20. PubMed ID: 20881647 [TBL] [Abstract][Full Text] [Related]
18. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400 [TBL] [Abstract][Full Text] [Related]
19. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323 [TBL] [Abstract][Full Text] [Related]
20. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Ceresoli GL; Castagneto B; Zucali PA; Favaretto A; Mencoboni M; Grossi F; Cortinovis D; Del Conte G; Ceribelli A; Bearz A; Salamina S; De Vincenzo F; Cappuzzo F; Marangolo M; Torri V; Santoro A Br J Cancer; 2008 Jul; 99(1):51-6. PubMed ID: 18542071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]